PEP-Therapy and CleveXel Pharma will co-develop targeted therapy in oncology. The product is based on an innovative technology involving bi-functional peptides that penetrate cells, and specifically block pathological mechanisms without affecting physiological mechanisms.
The drug candidate is a cell-penetrating peptide that targets an interaction between two intracellular proteins, Caspase-9 and PP2A. It has been validated on highly-representative preclinical models for human tumors, such as patient-derived xenograft or PDX models. The approach showed targeted efficacy on cancer cells and an absence of toxicity, especially in triple-negative breast cancer and ovarian cancer.
The partners’ mutual goal is to take the product through to its clinical proof of concept with both costs and benefits being shared. PEP-Therapy intends to benefit from CleveXel’s acceleration programm. This development system already contains two other oncology candidates that are currently profiting from CleveXel’s expertise.
PEP-Therapy, thanks to this partnership, will accelerate the development of its first product towards its clinical trial phase, which is expected to start at the end of 2016.